Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
暂无分享,去创建一个
T. Matthews | C. McDanal | C. Wild | D. Shugars | C. Wild | T. Greenwell | T J Matthews | D C Shugars | C T Wild | T K Greenwell | C B McDanal | C. McDanal | Teresa Greenwell
[1] M. Mulligan,et al. Oligopeptide inhibitors of HIV-induced syncytium formation. , 1990, AIDS research and human retroviruses.
[2] A. Dalgleish,et al. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. , 1988, Virology.
[3] J. Rose,et al. Mutations in the membrane-spanning domain of the human immunodeficiency virus envelope glycoprotein that affect fusion activity , 1994, Journal of virology.
[4] L. Henderson,et al. A peptide inhibitor of human immunodeficiency virus infection binds to novel human cell surface polypeptides. , 1993, The Journal of biological chemistry.
[5] J. Sodroski,et al. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. , 1987, Science.
[6] E. Hunter,et al. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity , 1992, Journal of virology.
[7] J. Goudsmit,et al. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies , 1993, Journal of virology.
[8] T. Oas,et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[9] L. Arthur,et al. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[10] M. Greaves,et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.
[11] W. Gallaher,et al. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus , 1987, Cell.
[12] S. Jiang,et al. Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41. , 1993, Biochemical and biophysical research communications.
[13] R. Arlinghaus,et al. Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120 , 1993, Journal of virology.
[14] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[15] H. Katinger,et al. HIV‐1 gp41 contains two sites for interaction with several proteins on the helper T‐lymphoid cell line, H9 , 1992, AIDS.
[16] R. Garry,et al. A general model for the transmembrane proteins of HIV and other retroviruses. , 1989, AIDS research and human retroviruses.
[17] C. N. Lee,et al. Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein , 1993, Journal of virology.
[18] D. Ho,et al. High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[19] E. Hunter,et al. Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells , 1993, Journal of virology.
[20] J. Sodroski,et al. Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein , 1991, Journal of virology.
[21] J. Sodroski,et al. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein , 1993, Journal of virology.
[22] J. Sodroski,et al. Identification of Membrane Anchorage Domains of the HIV‐1 gp160 Envelope Glycoprotein Precursor , 1991, Journal of acquired immune deficiency syndromes.
[23] J. Sodroski,et al. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp120 third variable region and gp41 amino terminus , 1992, Journal of virology.
[24] J. Sodroski,et al. Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins , 1992, Journal of virology.
[25] J. Sodroski,et al. Changes in the transmembrane region of the human immunodeficiency virus type 1 gp41 envelope glycoprotein affect membrane fusion , 1990, Journal of virology.
[26] Jerome A. Zack,et al. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure , 1990, Cell.
[27] P. Earl,et al. Identification of the fusion peptide of primate immunodeficiency viruses. , 1989, Science.
[28] T. Matthews,et al. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. , 1993, AIDS research and human retroviruses.
[29] D. Coy,et al. Characterization of a putative cellular receptor for HIV-1 transmembrane glycoprotein using synthetic peptides. , 1990, AIDS.
[30] Gilcher Ro. Human retroviruses and AIDS. , 1988 .
[31] H. Edelhoch,et al. Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.